Cebix
Signal active
Organization
Contact Information
Overview
Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Founded
2008
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Cebix headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $9.7B in funding across 96 round(s). With a team of 1-10 employees, Cebix is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Cebix, raised $16.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
3
Lead Investors
0
Total Funding Amount
$101.4M
Details
2
Cebix has raised a total of $101.4M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2008 | Early Stage Venture | 2.9M | ||
| 2012 | Early Stage Venture | 33.2M |
Investors
Cebix is funded by 3 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Lars Ekman | - | FUNDING ROUND - Lars Ekman | 2.9M |
| Cebix | - | FUNDING ROUND - Cebix | 2.9M |
| Sofinnova Investments | - | FUNDING ROUND - Sofinnova Investments | 2.9M |
Recent Activity
There is no recent news or activity for this profile.